FW1256

117089-08-4

247.25

DMSO : >= 250 mg/mL (1011.12 mM)

Apoptosis; NF-kappaB

FW1256 is a phenyl analogue and a slow-releasing hydrogen sulfide (H₂S) donor. FW1256 inhibits NF-kappaB activity and induces cell apoptosis. FW1256 exerts potent anti-inflammatory effects and has the potential for cancer and cardiovascular disease treatment^[1][2]. In Vitro: FW1256 (200 uM; 24.5 hours; AW264.7 cells) treatment significantly reduces IL-1beta, COX-2 and iNOS mRNA and protein in LPS-stimulated RAW264.7 macrophages^[1].
FW1256 (200 uM; 24.5 hours; AW264.7 cells) treatment significantly reduces IL-1beta, COX-2 and iNOS PROTE and protein in LPS-stimulated RAW264.7 macrophages^[1].
FW1256 concentration dependently decreases TNF-alpha (IC₅₀ of 61.2 uM), IL-6 (IC₅₀ of 11.7 uM), PGE2 (IC₅₀ of 25.5 uM) and NO (IC₅₀ of 34.6 uM) generation in LPS-stimulated RAW264.7 macrophages and bone marrow-derived macrophages (BMDMs) (IC₅₀s of 414.9 uM, 300.2 uM, 4 uM and 9.5 uM for TNF-alpha, IL-6, PGE2 and NO, respectively) ^[1].
FW1256 decreases NF-kappaB activation as evidenced by reduced cytosolic phospho-IkappaBalpha levels and reduces nuclear p65 levels in LPS-stimulated RAW264.7 macrophages treated with FW1256^[1]. In Vivo: FW1256 (100 mg/kg; intraperitoneal injection; male C57BL/6 mice) treatment reduces IL-1beta, TNFalpha, nitrate/nitrite and PGE2 levels in LPS-treated mice^[1].